AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 6:14 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 6:14 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Here's Why You Should Add Glaukos (GKOS) to Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like AMN, OTTR, ECPG and CBOE that are seeing price strength have a high chance of carrying the momentum forward.
Zacks.com featured highlights include JSanderson Farms, Otter Tail, J&J Snack Foods and AMN Healthcare
by Zacks Equity Research
JSanderson Farms, Otter Tail, J&J Snack Foods and AMN Healthcare are part of Screen of the Week article.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), given its better-than-expected earnings and strategic alliances.
Cardinal Health's (CAH) New Buyout to Boost Medication Adherence
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly improve patients' health outcomes with improved medication adherence and increased satisfaction.
Buy These 4 Low-Beta Stocks to Sail Through a Volatile Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Sanderson (SAFM), Otter Tail (OTTR), J&J Snack Foods (JJSF) and AMN Healthcare (AMN) are well poised to gain.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to gain momentum from a solid product portfolio and a strong General Surgery business. However, data security issues linger.
Factors that Make Acadia Healthcare (ACHC) an Attractive Bet Now
by Zacks Equity Research
Solid demand for behavioral healthcare services, growth-related efforts in the form of JVs, declining debt burden and sufficient cash-generating abilities continue to benefit Acadia Healthcare (ACHC).
Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base
by Zacks Equity Research
Henry Schein (HSIC) serves the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004.
Merit Medical's (MMSI) New Launch to Improve Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest launch will likely aid in precisely targeting affected tissues, thereby resulting in more successful surgeries and improved patient outcomes.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal
by Zacks Equity Research
Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.
LabCorp's (LH) Base Testing Volume Grows, Costs Rise
by Zacks Equity Research
LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
Here's Why You Should Retain Haemonetics (HAE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Bruker (BRKR) Debuts NMR Test for Research on Long COVID Risks
by Zacks Equity Research
Bruker's (BRKR) PhenoRisk PACS RuO will facilitate clinical research to combat the risks of Long COVID syndrome.
Cardinal Health (CAH) Buys Bendcare CPO-GPO, Invests in Its MSO
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly boost its distribution opportunities and improve patient service.
LabCorp (LH) to Offer Monkeypox Test, Double CDC's Capacity
by Zacks Equity Research
Labcorp (LH) is set to become the first national laboratory to offer this PCR test, verified for the CDC.
AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $110.47, moving -0.11% from the previous trading session.
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.
Reasons Why You Should Invest in ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
Study Favors Masimo's (MASI) SafetyNet for Better Patient Outcome
by Zacks Equity Research
Masimo's (MASI) SafetyNet is expected to reduce the duration of hospitalization for COVID-19 patients and create more bed capacity in hospitals.
Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes
by Zacks Equity Research
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.